Skip to search formSkip to main contentSkip to account menu

GV 150526A

Known as: GV-150526A, GV150526, GV150526A 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2002
Review
2002
Neuroprotective agents in acute ischemic stroke.
The concept of neuroprotection relies on the principle that delayed neuronal injury occurs after ischemia. The phenomenon of the… 
Highly Cited
2001
Highly Cited
2001
Glycine Antagonist (GV150526) in Acute Stroke: A Multicentre, Double-Blind Placebo-Controlled Phase II Trial
GV150526 is a novel glycine antagonist at the NMDA receptor complex. It is a potent neuroprotective agent in animal models of… 
2001
2001
The neuroprotective activity of the glycine receptor antagonist GV150526: an in vivo study by magnetic resonance imaging.
2001
2001
Physicochemical study of the solid forms of a new drug.
GV150526A is a new drug recently developed by GlaxoWellcome. It belongs to a novel group of 2-carboxyindole derivatives and is… 
2000
2000
Human hepatic metabolism of a novel 2-carboxyindole glycine antagonist for stroke: in vitro-in vivo correlations
1. The hepatic metabolism of 3-[-2(phenylcarbamoyl) ethenyl]-4,6-dichloroindole-2-carboxylic acid (GV150526), a novel glycine… 
1999
1999
Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia.
A series of analogues of the indole-2-carboxylate GV150526, currently in clinical trials as a potential neuroprotective agent for… 
1999
1999
The neuroprotective glycine receptor antagonist GV150526 does not produce neuronal vacuolization or cognitive deficits in rats.
Review
1999
Review
1999
Substituted Indole‐2‐carboxylates as Potent Antagonists of the Glycine Binding Site Associated with the NMDA Receptor
A novel series of indole‐2‐carboxylate analogues of GV150526 (1) in which the propenoic double bond was substituted with… 
1998
1998
IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF GV150526, A NOVEL GLYCINE ANTAGONIST AS A POTENT NEUROPROTECTIVE AGENT
1997
1997
Post-ischemic recovery of acetylcholine release in vitro: influence of different excitatory amino acid receptor subtype antagonists
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)